Stock Events

Stock Events

Palatin Technologies 

€12.5
0
-€2.5-16.67% Friday 19:35

Statistics

Day High
12.5
Day Low
0.2
52W High
30
52W Low
0.2
Volume
167,050
Avg. Volume
0
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

19MayExpected
Q4 2025
Next
-2.41
-1.96
-1.51
-1.06
Expected EPS
-1.06104794887
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PTN.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap178B
Amgen develops therapeutics in areas similar to Palatin, including reproductive health and cardiovascular diseases, making them direct competitors in the biopharmaceutical market.
Pfizer
PFE
Mkt Cap149.77B
Pfizer competes with Palatin in the development of novel drugs, including treatments in sexual health, where Palatin has a significant focus.
Lilly(Eli) &
LLY
Mkt Cap862.01B
Eli Lilly offers products in men's health and other areas that overlap with Palatin's focus, particularly in treatments for conditions like erectile dysfunction.
Abbvie
ABBV
Mkt Cap365.43B
AbbVie, with its broad range of pharmaceutical products, competes in the same therapeutic areas as Palatin, including women's health and hormonal therapies.
Merck
MRK
Mkt Cap277.02B
Merck operates in various healthcare segments that compete with Palatin, including the development of drugs for sexual health and cardiovascular diseases.
Novartis
NVS
Mkt Cap279.67B
Novartis competes with Palatin in multiple areas, including cardiovascular and metabolic conditions, through its extensive research and development in these fields.
Bristol-Myers Squibb
BMY
Mkt Cap118.87B
Bristol Myers Squibb's diverse range of pharmaceutical products in areas like cardiovascular diseases places it in competition with Palatin Technologies.
GSK
GSK
Mkt Cap103.01B
GlaxoSmithKline has a presence in the sexual health market, making it a competitor to Palatin, especially in the development of treatments for related conditions.
Astrazeneca
AZN
Mkt Cap286.4B
AstraZeneca's work in cardiovascular and metabolic diseases competes with Palatin's research and development efforts in similar therapeutic areas.

About

Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.
Show more...
CEO
Dr. Carl Spana Ph.D.
Employees
29
Country
United States
ISIN
US6960776010

Listings

STU
DE
PTN.STU
LSE
GB
0KF3.LSE
XASE
US
PTN
BOATS
BOATS
PTN.BOATS

0 Comments

Share your thoughts

FAQ

What is Palatin Technologies stock price today?▼
The current price of PTN.STU is €12.5 EUR — it has decreased by -16.67% in the past 24 hours. Watch Palatin Technologies stock price performance more closely on the chart.
What is Palatin Technologies stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Palatin Technologies stocks are traded under the ticker PTN.STU.
Is Palatin Technologies stock price growing?▼
PTN.STU stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Palatin Technologies has showed a +75.07% increase.
When is the next Palatin Technologies earnings date?▼
Palatin Technologies is going to release the next earnings report on May 19, 2026.
What were Palatin Technologies earnings last quarter?▼
PTN.STU earnings for the last quarter are -2.41 EUR per share, whereas the estimation was -1.99 EUR resulting in a -21.53% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Palatin Technologies have?▼
As of May 06, 2026, the company has 29 employees.
In which sector is Palatin Technologies located?▼
Palatin Technologies operates in the Manufacturing sector.
When did Palatin Technologies complete a stock split?▼
The last stock split for Palatin Technologies was on August 11, 2025 with a ratio of 1:50.
Where is Palatin Technologies headquartered?▼
Palatin Technologies is headquartered in Monmouth Junction, United States.